Proveca medicines for children
This section is intended for Healthcare Professionals only and contains promotional content.
Sialanar® received a Paediatric Use Marketing Authorisation (PUMA) in September 2016 for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
If you would like to find out further information on Sialanar® (including various educational and supporting resources) please visit the Sialanar® website.
Please see information below to report adverse events in the Republic of Ireland